Qiming U.S. Ventures Management, LLC

Est. AUM

$55.6M

13F long equity, this entity only

Positions

Period

Sep 2025 (Q3)

SEC EDGAR

Sep 2025 (Q3)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	TOURMALINE BIO INC	COM	$35.5M	741691	63.76%	SOLE
2	KORRO BIO INC	COM	$17.6M	368085	31.68%	SOLE
3	JASPER THERAPEUTICS INC	COM NEW	$2.2M	928964	3.97%	SOLE
4	KEZAR LIFE SCIENCES INC	COM NEW	$323K	82871	0.58%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.